← Russell 3000 cross-section

TRLV Trulieve Cannabis Corp.

Trailing twelve months to 2026-06-30 · as filed 2026-08-07, not restated
Healthcare

Scale

Market cap
$2.2bn
Revenue TTM
$1.1bn
Net income TTM
$-476m
Free cash flow
$195m
Composite score
55.0
Sector rank
#1595

Valuation

P / E
EV / EBITDA
EV / sales
1.8
FCF yield
8.94%
Earnings yield vs 10-yr
-26.60pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-41.8%
EBITDA margin
ROE
-62.2%
ROIC
-43.6%
Revenue growth
-3.9%

Insider activity, last 90 days

Net open-market
$-14.66m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Operations and sales trends in select markets do follow seasonal trends at various times of the year, providing seasonal impacts on sales in summer and winter months and increases from promotional activity around specific industry and holiday events including 4/20, 7/10, and Green Wednesday (the Wednesday before Thanksgiving). Equity Method Investment. The following table and discussion compares condensed consolidated statements of operations data for the quarter-to-date periods presented: Revenue Revenue for the three months ended June 30, 2026 was $271.0 million, a decrease of $31.1 million, from $302.1 million for the three months ended June 30, 2025. …Trulieve Cannabis Corp., 10-Q, period ended 2026-06-30, filed 2026-08-07

Read the full passage →